Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | PLA2G2A | P14555 | 8/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13600643 | 0.86 | TSHR (0.52) | TSHRTHRBPLA2G2AKMT2AMAPT | |
| SCHEMBL18390528 | 0.85 | TSHR (0.60) | TSHRTHRBKMT2AMAPTALDH1A1 | |
| SCHEMBL13600599 | 0.85 | TSHR (0.53) | TSHRTHRBPLA2G2AKMT2AMAPT | |
| SCHEMBL2360551 | 0.80 | KMT2A (0.62) | TSHRTHRBKMT2AMAPTALDH1A1 | |
| SCHEMBL18483472 | 0.74 | KMT2A (0.67) | TSHRKMT2AMAPTALDH1A1CHRNA4 | |
| SCHEMBL25676108 | 0.74 | KMT2A (0.56) | TSHRTHRBKMT2AMAPTALDH1A1 | |
| SCHEMBL13607425 | 0.74 | PLA2G2A (0.52) | THRBPLA2G2AALDH1A1CHRNA4 | |
| SCHEMBL18390550 | 0.73 | KMT2A (0.58) | TSHRTHRBKMT2AMAPTALDH1A1 | |
| SCHEMBL15566378 | 0.73 | CHRNA4 (0.62) | TSHRTHRBKMT2AMAPTALDH1A1 | |
| SCHEMBL2606197 | 0.72 | NPC1 (0.60) | TSHRTHRBKMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765830-B1 | MITOTIC KINESIN INHIBITORS | MERCK SHARP & DOHME (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7632833-B2 | Anticancer agents | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20080287414-A1 | Mitotic Kinesin Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287414-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF18B | TSHR 4668/4885THRB 4418/4885PLA2G2A 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.